Augmented Passive Immunotherapy with P4 Peptide Improves Phagocyte Activity in Severe Sepsis
Open Access
- 1 December 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Shock
- Vol. 46 (6), 635-641
- https://doi.org/10.1097/shk.0000000000000715
Abstract
Introduction: Antimicrobial resistance threatens to undermine treatment of severe infection; new therapeutic strategies are urgently needed. Preclinical work shows that augmented passive immunotherapy with P4 peptide increases phagocytic activity and shows promise as a novel therapeutic strategy. Our aim was to determine ex vivo P4 activity in a target population of patients admitted to critical care with severe infection. Methods: We prospectively recruited UK critical care unit patients with severe sepsis and observed clinical course (≥3 months postdischarge). Blood samples were taken in early (≤48 h postdiagnosis, n = 54), latent (7 days postdiagnosis, n = 39), and convalescent (3–6 months postdiagnosis, n = 18) phases of disease. The primary outcome measure was killing of opsonized Streptococcus pneumoniae by neutrophils with and without P4 peptide stimulation. We also used a flow cytometric whole blood phagocytosis assay to determine phagocyte association and oxidation of intraphagosomal reporter beads. Results: P4 peptide increased neutrophil killing of opsonized pneumococci by 8.6% (confidence interval 6.35–10.76, P < 0.001) in all phases of sepsis, independent of infection source and microbiological status. This represented a 54.9% increase in bacterial killing compared with unstimulated neutrophils (15.6%) in early phase samples. Similarly, P4 peptide treatment significantly increased neutrophil and monocyte intraphagosomal reporter bead association and oxidation, independent of infection source. Conclusions: We have extended preclinical work to demonstrate that P4 peptide significantly increases phagocytosis and bacterial killing in samples from a target patient population with severe sepsis. This study supports the rationale for augmented passive immunotherapy as a therapeutic strategy in severe sepsis.Keywords
This publication has 32 references indexed in Scilit:
- Trial of Early, Goal-Directed Resuscitation for Septic ShockNew England Journal of Medicine, 2015
- Goal-Directed Resuscitation for Patients with Early Septic ShockNew England Journal of Medicine, 2014
- Immunomodulatory adjuvant therapy in severe community-acquired pneumoniaExpert Review of Respiratory Medicine, 2014
- A Randomized Trial of Protocol-Based Care for Early Septic ShockNew England Journal of Medicine, 2014
- A Novel Innate Immune-Enhancement Strategy Combined with IVIG Rescues Mice from FatalStaphylococcus aureusSepticemiaInternational Journal of Microbiology, 2011
- P4 Peptide Therapy Rescues Aged Mice from Fatal Pneumococcal SepsisClinical and Vaccine Immunology, 2010
- An Augmented Passive Immune Therapy to Treat Fulminant Bacterial InfectionsRecent Patents on Anti-Infective Drug Discovery, 2010
- Evaluation of a Novel Therapeutic Approach to Treating Severe Pneumococcal Infection Using a Mouse ModelClinical and Vaccine Immunology, 2009
- A 28?aa Pneumococcal Surface Adhesin A–Derived Peptide, P4, Augments Passive Immunotherapy and Rescues Mice from Fatal Pneumococcal InfectionThe Journal of Infectious Diseases, 2009
- A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalizationMicrobial Pathogenesis, 2008